Hamps Bio shares debuted with a 90% premium on Friday, listing at ₹96.90 on the BSE SME platform, above the ₹51 issue price. The stock was trading at a ₹60 GMP in the grey market prior to the listing.
Also Read: Travel stock in focus after it partners with OLX for travel booking
Hamps Bio Ltd raised ₹6.22 crore through its IPO, which saw overwhelming demand, with an overall subscription of 1,057 times. The retail portion was oversubscribed 1,342 times, and the non-institutional investors’ category was booked 758 times.
Hamps Bio Limited markets pharmaceutical formulations under “Hamps” and freeze-dried FMCG products under “FzyEzy.” It sells 180+ products across 8 Indian states and 6 countries. With in-house manufacturing in Gujarat, the company serves B2B and expanding B2C markets via distributors and e-commerce platforms.
Also Read: Stock hits 5% upper circuit after company announces fundraise
The objective of Hamps Bio Ltd’s IPO is to raise funds for expanding its business operations, enhancing infrastructure, and strengthening its market presence. The capital will also support working capital requirements and funding future growth initiatives in the biotechnology sector.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.